Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | tar DNA-binding protein | 0.006 | 0.2932 | 0.2932 |
Mycobacterium tuberculosis | Probable short-chain type dehydrogenase/reductase | 0.0066 | 0.3388 | 1 |
Entamoeba histolytica | Acid sphingomyelinase-like phosphodiesterase, putative | 0.0078 | 0.4214 | 0.5 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0062 | 0.3073 | 0.7293 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0018 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.006 | 0.2932 | 0.8654 |
Echinococcus multilocularis | tar DNA binding protein | 0.006 | 0.2932 | 0.2932 |
Loa Loa (eye worm) | TAR-binding protein | 0.006 | 0.2932 | 0.6958 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.006 | 0.2932 | 0.6958 |
Trypanosoma cruzi | isocitrate dehydrogenase, putative | 0.0018 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.006 | 0.2932 | 0.2932 |
Echinococcus granulosus | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0066 | 0.3388 | 0.3388 |
Plasmodium vivax | isocitrate dehydrogenase [NADP], mitochondrial, putative | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.006 | 0.2932 | 0.2932 |
Brugia malayi | TAR-binding protein | 0.006 | 0.2932 | 0.8654 |
Brugia malayi | RNA binding protein | 0.006 | 0.2932 | 0.8654 |
Echinococcus multilocularis | geminin | 0.016 | 1 | 1 |
Echinococcus multilocularis | 3 hydroxyacyl coenzyme A dehydrogenase type 2 | 0.0066 | 0.3388 | 0.3388 |
Schistosoma mansoni | hypothetical protein | 0.016 | 1 | 1 |
Leishmania major | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0066 | 0.3388 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.006 | 0.2932 | 0.2932 |
Entamoeba histolytica | Acid sphingomyelinase-like phosphodiesterase, putative | 0.0078 | 0.4214 | 0.5 |
Trypanosoma brucei | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0018 | 0 | 0.5 |
Trypanosoma cruzi | isocitrate dehydrogenase [NADP], mitochondrial precursor, putative | 0.0018 | 0 | 0.5 |
Toxoplasma gondii | isocitrate dehydrogenase | 0.0018 | 0 | 0.5 |
Brugia malayi | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0066 | 0.3388 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.003 | 0.0844 | 0.2004 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0066 | 0.3388 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.006 | 0.2932 | 0.2932 |
Loa Loa (eye worm) | RNA binding protein | 0.006 | 0.2932 | 0.6958 |
Mycobacterium ulcerans | short-chain type dehydrogenase/reductase | 0.0066 | 0.3388 | 0.5 |
Trypanosoma brucei | isocitrate dehydrogenase, putative | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | 3-hydroxyacyl-CoA dehydrogenase | 0.0066 | 0.3388 | 0.3388 |
Schistosoma mansoni | hypothetical protein | 0.016 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0078 | 0.4214 | 1 |
Plasmodium falciparum | isocitrate dehydrogenase [NADP], mitochondrial | 0.0018 | 0 | 0.5 |
Brugia malayi | Cytochrome P450 family protein | 0.003 | 0.0844 | 0.2492 |
Schistosoma mansoni | tar DNA-binding protein | 0.006 | 0.2932 | 0.2932 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | = 0.54 uM | Antiproliferative activity against human WI38 cells after 72 hrs by MTT assay | ChEMBL. | 21439689 |
IC50 (functional) | = 60.24 uM | Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay | ChEMBL. | 21439689 |
IC50 (functional) | > 100 uM | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay | ChEMBL. | 21439689 |
IC50 (functional) | > 100 uM | Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay | ChEMBL. | 21439689 |
IC50 (functional) | > 100 uM | Antiproliferative activity against human MIAPaCa2 after 72 hrs by MTT assay | ChEMBL. | 21439689 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 21439689 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.